Market Research Reports

U.S. Vaccine Market - Industry Analysis, Size, Share, Growth, And Forecast 2012 - 2018

82pages
Published Date: 2012-09-13
 

Description



The U.S. vaccine market research report presents statics, information, and expert recommendations that will help key stakeholders in this market to formulate stable growth strategies. The U.S. vaccines market is composed of numerous segments, and this report studies each of them in meticulous detail. The report will help market players (and other ancillary organizations) zero in on factors that will bring about the expansion of the U.S. vaccine market over the forecast period of 2012 to 2018. The sub-markets that will likely be linked to the core U.S. vaccine market are also studied in the report. 

Among the key takeaways from this report are: an ability to pinpoint the current trends, indentify challenges, formulate better financial models based on projected risks, understand the competitive structure and market shares of companies, gain insight into emerging opportunities and ways to harness them.

For the purpose of this study, the U.S. vaccine market has been segmented on the basis of product type. The applications, geographical share, and forecasts for each of these product types have been provided in the market research report. The annual forecasts are provided in USD million, and are for the period ranging from 2012 through 2018.

Overview of the U.S. Vaccine Market

According to the findings of this market research report, the U.S. vaccine market will notch a value of US$ 17.4 billion by 2018. The market stood at US$ 12.8 billion as of 2012, which means that the CAGR of the U.S. vaccine market will be approximately 5.3% between 2012 and 2018.

Many leading vaccines formulated for illnesses and disorders have proven to be major money spinners for the American pharmaceutical industry in recent years. The U.S. vaccine market is characterized by intensive and amply-funded R&D initiatives that have resulted in the launch of more effective and high-quality vaccines and drugs for a number of common and rare illnesses. The sales of vaccines in the United States have reported a higher growth rate than that of prescription drugs. The revenue growth from vaccine production has also demonstrated an upswing, which has encouraged many market players to invest more in the U.S. vaccine market. All of these factors have taken the U.S. vaccine industry to enormous proportions.

While drugs in the generic segments typically face stiff competition, the sales of vaccines are largely resistant to these factors. Top-selling vaccine treatments have earned pharma companies billions of dollars worth of revenue thus far. One of the largest customers for the vaccines market is government funded or supporting agencies (in the U.S. and abroad). Many of these vaccines are in demand for treating infectious diseases in both animals and humans. The scale of revenues resulting from this business arm has prompted the U.S. to maintain a steady focus on producing vaccines.

Market Segments Analysis

This market research report studies all major segments within the U.S. vaccine market. At the first level, the U.S. vaccine market is segmented as human vaccines, animal vaccines, and companion animal vaccines. The former is further split into: pediatric vaccines, adult and adolescent vaccines, and other human vaccines. The animal vaccines market is similarly segregated as: livestock, bovine, ovine, and porcine vaccine. The companion animal vaccine segment is divided as: feline, canine, equine, and other animal vaccine.

Companies mentioned in the U.S. vaccine market research report

The eminent names in the U.S. vaccine market that have been featured in this market research report include: Pfizer, Merck, GlaxoSmithKline, Sanofi-Aventis, Novartis, and Sanofi-Pasture. 
The U.S. is the leading producer of animal vaccines in the world. Within this segment, leading competitors are: Merial (Sanofi-Aventis), Novartis Animal Health, Pfizer Animal Health, and Intervet/Schering-Plough (Merck).

This report gives you access to decisive data such as:
  • Market growth drivers 
  • Factors limiting market growth
  • Current market trends 
  • Market structure
  • Market projections for the coming years 
Key higights of this report
  • Study chronological sales performance of the overall and regional U.S. vaccine market
  • Obtain sales forecasts U.S. vaccines that are currently marketed for 2012 – 2018
  • Overview of key market forces propelling and restraining market growth 
  • Up-to-date analyses of market trends and technological improvements 
  • Pin-point analyses of market competition dynamics to offer you a competitive edge
  • An analysis of strategies of major competitors 
  • An array of graphics and SWOT analysis of major industry segments 
  • Detailed analyses of industry trends
  • A well-defined technological growth map with an impact-analysis 
  • Offers a clear understanding of the competitive landscape and key product segments

Table of Contents


TABLE OF CONTENTS

CHAPTER 1 INTRODUCTION
1.1 REPORT DESCRIPTION
1.2 METHODOLOGY

CHAPTER 2 EXECUTIVE SUMMARY

CHAPTER 3 U.S. VACCINE MARKET, 2012 - 2018
3.1 MARKET OVERVIEW
3.2 VACCINE MARKET CHARACTERISTICS
3.3 LAWS AND REGULATIONS
3.3.1 VACCINE APPROVAL PROCESS
3.4 U.S. VACCINE MARKET ESTIMATE AND FORECAST, 2012 - 2018
3.4.1 MARKET SHARE BY VACCINE TYPE
3.5 LIST OF COMPANIES SUPPLYING VACCINES IN THE U.S.
3.6 VACCINE PRICING
3.6.1 PRICES FOR VACCINES CONTAINING THIMEROSAL AS A PRESERVATIVE
3.6.2 PRICES OF VACCINES FREE OF PRESERVATIVES:
3.7 MARKET DYNAMICS
      3.7.1 DRIVERS
              3.7.1.1 Rise in incidences of viral infection driving the growth of vaccine market in the U.S.
              3.7.1.2 Biotechnology research enabling synthesis of new vaccines to target complex human diseases driving the vaccine market
              3.7.1.3 Government recommendation for adult and adolescent immunization will boost the growth of Vaccine market in U.S.
              3.7.1.4 Rise in infectious diseases in animals driving the market
      3.7.2 RESTRAINTS
              3.7.2.1 Cost of refrigeration
              3.7.2.2 Short functional shelf life of certain vaccines will have negative impact on the market growth
     3.7.3 OPPORTUNITIES
              3.7.3.1 Huge product pipeline of the multinational firms will act as an opportunity for future growth
3.8 IMPACT ANALYSIS OF DRIVERS
3.9 IMPACT ANALYSIS OF RESTRAINTS
3.10 PORTER’S FIVE FORCE ANALYSIS
       3.10.1 BARGAINING POWER OF SUPPLIER
       3.10.2 BARGAINING POWER OF BUYER
       3.10.3 RIVALRY AMONG EXISTING COMPETITORS
       3.10.4 THREAT OF NEW ENTRANTS
       3.10.5 THREAT OF SUBSTITUTE

CHAPTER 4 U.S. VACCINE MARKET BY PRODUCT TYPE
4.1 HUMAN VACCINE
       4.1.1 MARKET ANALYSIS, SIZE AND FORECAST
       4.1.2 MARKET ATTRACTIVENESS ANALYSIS FOR HUMAN VACCINE MARKET
       4.1.3 PEDIATRIC VACCINES
               4.1.3.1 Market Analysis, Size and Forecast
               4.1.3.2 Pediatric vaccine price list
               4.1.3.3 Pediatric Influenza Vaccine price list
               4.1.3.4 HaemophilusInfluenzae Type B
                          4.1.3.4.1 Hib Pricing
               4.1.3.5 Hepatitis A
                          4.1.3.5.1 HAV Pricing
               4.1.3.6 Hepatitis B
                          4.1.3.6.1 Hepatitis B Pricing
      4.1.4 ADULT & ADOLESCENT VACCINES
               4.1.4.1 Market Analysis, Size and Forecast
               4.1.4.2 Adult vaccine price list
               4.1.4.3 Adult Influenza Vaccine price list
      4.1.5 OTHER HUMAN VACCINES
              4.1.5.1 Market Analysis, Size and Forecast
4.2 ANIMAL VACCINE
      4.2.1 MARKET ANALYSIS, SIZE AND FORECAST
      4.2.2 MARKET ATTRACTIVENESS ANALYSIS FOR ANIMAL VACCINE
      4.2.3 LIVESTOCK VACCINES
              4.2.3.1 Market Analysis, Size and Forecast
              4.2.3.2 Bovine Vaccines
                         4.2.3.2.1 Market Analysis, Size and Forecast
              4.2.3.3 Porcine Vaccines
                         4.2.3.3.1 Market Analysis, Size and Forecast
              4.2.3.4 Ovine Vaccines
                         4.2.3.4.1 Market Analysis, Size and Forecast
     4.2.4 COMPANION ANIMAL VACCINES
              4.2.4.1 Market Analysis, Size and Forecast
              4.2.4.2 Feline Vaccines
                         4.2.4.2.1 Market Analysis, Size and Forecast
              4.2.4.3 Canine Vaccines
                         4.2.4.3.1 Market Analysis, Size and Forecast
              4.2.4.4 Equine Vaccines
                         4.2.4.4.1 Market Analysis, Size and Forecast
      4.2.5 OTHER ANIMAL VACCINES
              4.2.5.1 Market Analysis, Size and Forecast

CHAPTER 5 COMPETITIVE LANDSCAPE
5.1 MARKET SHARE ANALYSIS
5.2 COMPETITIVE ANALYSIS FOR KEY MARKET PLAYERS

CHAPTER 6 COMPANY PROFILE
6.1 SANOFI-AVENTIS
      6.1.1 COMPANY OVERVIEW
      6.1.2 FINANCIAL OVERVIEW
      6.1.3 SWOT ANALYSIS
      6.1.1 RECENT DEVELOPMENT
6.2 GLAXOSMITHKLINE
      6.2.1 COMPANY OVERVIEW
      6.2.2 FINANCIAL OVERVIEW:
      6.2.3 SEGMENT OVERVIEW
      6.2.4 SWOT ANALYSIS
      6.2.5 RECENT DEVELOPMENTS
6.3 MERCK & COMPANY INCORPORATED
      6.3.1 COMPANY OVERVIEW
      6.3.2 FINANCIAL OVERVIEW:
      6.3.1 RECENT DEVELOPMENT
6.4 PFIZER INCORPORATED
      6.4.1 COMPANY OVERVIEW
      6.4.2 FINANCIAL OVERVIEW
      6.4.3 RECENT DEVELOPMENT
6.5 ASTRAZENECA PLC
      6.5.1 COMPANY OVERVIEW
      6.5.2 FINANCIAL OVERVIEW:
      6.5.3 RECENT DEVELOPMENT
6.6 NOVARTIS AG
      6.6.1 COMPANY OVERVIEW
      6.6.2 FINANCIAL OVERVIEW:
      6.6.3 SWOT ANALYSIS
      6.6.1 RECENT DEVELOPMENT
6.7 BOEHRINGER
      6.7.1 COMPANY OVERVIEW
      6.7.2 NET SALES BY BUSINESS
      6.7.3 SWOT ANALYSIS
      6.7.4 RECENT DEVELOPMENT

LIST OF FIGURES

FIG. 1 U.S. VACCINE MARKET REVENUE, BY PRODUCT TYPE, 2012 - 2018, (USD MILLION) 
FIG. 2 FDA REGULATORY REVIEW PROCESS 
FIG. 3 VACCINE APPROVAL PROCESS 
FIG. 4 U.S. VACCINE MARKET REVENUE, 2010 - 2018 (USD MILLION) 
FIG. 5 U.S. VACCINE MARKET SHARE, BY VACCINE TYPE 2012 ESTIMATE (%) 
FIG. 6 IMPACT ANALYSIS OF DRIVERS 
FIG. 7 PORTER’S FIVE FORCE ANALYSIS FOR U.S. VACCINE MARKET 
FIG. 8 U.S. HUMAN VACCINE MARKET REVENUE2010 - 2018(USD MILLION) 
FIG. 9 MARKET ATTRACTIVENESS ANALYSIS FOR U.S. HUMAN VACCINE MARKET 
FIG. 10 PEDIATRIC VACCINES MARKET REVENUE 2010 – 2018 (USD MILLION) 
FIG. 11 ADULT & ADOLESCENT VACCINESMARKET  REVENUE 2010 - 2018  (USD MILLION) 
FIG. 12 OTHER HUMAN VACCINESMARKET  REVENUE2010 - 2018  (USD MILLION) 
FIG. 13 U.S. ANIMAL VACCINEMARKET  REVENUE2010 - 2018 (USD MILLION) 
FIG. 14 MARKET ATTRACTIVENESS FOR U.S. ANIMAL VACCINE MARKET  2012 
FIG. 15 LIVESTOCK VACCINESMARKET  REVENUE2010 - 2018 (USD MILLION) 
FIG. 16 BOVINE VACCINES MARKET  REVENUE 2010 - 2018 (USD MILLION) 
FIG. 17 PORCINE VACCINESMARKET  REVENUE2010 - 2018 (USD MILLION) 
FIG. 18 OVINE VACCINES MARKET  REVENUE2010 - 2018 (USD MILLION) 
FIG. 19 COMPANION ANIMAL VACCINESMARKET  REVENUE2010 - 2018 (USD MILLION), 
FIG. 20 FELINE VACCINESMARKET  REVENUE2010-2018 (USD MILLION) 
FIG. 21 CANINE VACCINESMARKET  REVENUE2010 - 2018 (USD MILLION) 
FIG. 22 EQUINE VACCINESMARKET  REVENUE2010 - 2018 (USD MILLION) 
FIG. 23 OTHER ANIMAL VACCINESMARKET  REVENUE2010 - 2018 (USD MILLION) 
FIG. 24 MARKET SHARE OF MAJOR HUMAN VACCINE PRODUCERS IN THE U.S., 2011 (%) 
FIG. 25 MARKET SHARE OF MAJOR ANIMAL VACCINE PRODUCERS IN THE U.S., 2011 (%) 
FIG. 26 GLOBAL VACCINE PLAYERS SALES GROWTH 2012-2018 
FIG. 27 SANOFI-AVENTIS, PERFORMANCE CHART (2009-2011) 
FIG. 28 SANOFI-AVENTIS, SWOT ANALYSIS 
FIG. 29 GLAXOSMITHKLINE PLC AG, PERFORMANCE CHART (2006-2010) 
FIG. 30 GLAXOSMITHKLINE PLC AG, MARKET SHARE BY SEGMENT IN 2011 
FIG. 31 GLAXOSMITHKLINE PLC AG, SWOT ANALYSIS 
FIG. 32 MERCK & CO. , PERFORMANCE CHART (2007-2011) 
FIG. 33 MERCK, SWOT ANALYSIS 
FIG. 34 MERCK & CO. , PERFORMANCE CHART (2007-2011) 
FIG. 35 ASTRAZENECA PLC, MARKET SHARE BY SEGMENT IN 2011 
FIG. 36 ASTRAZENECA PLC, SWOT ANALYSIS 
FIG. 37 NOVARTIS AG, PERFORMANCE CHART (2007-2011) 
FIG. 38 NOVARTIS AG, SWOT ANALYSIS 
FIG. 39 BOEHRINGER, SWOT ANALYSIS 

LIST OF TABLES

TABLE 1 ACTS AND REGULATIONS PERTINENT TO VACCINE DEVELOPMENT 
TABLE 2 SELECT FDA AND ICH GUIDANCE DOCUMENTS RELEVANT TO VACCINE DEVELOPMENT 
TABLE 3 LOT-RELEASE TESTING GUIDLINES 
TABLE 1 U.S. VACCINE MARKET REVENUE, BY PRODUCT TYPE, 2012 - 2018, (USD MILLION) 
TABLE 2 GSK PRODUCT PIPELINE 
TABLE 3 U.S. HUMAN VACCINE MARKET REVENUE, BY PRODUCT TYPE 2012 - 2018 (USD MILLION) 
TABLE 4 U.S. ANIMAL VACCINE MARKET REVENUE, BY PRODUCT TYPE 2012 - 2018 (USD MILLION) 
TABLE 5 U.S. LIVESTOCK VACCINES MARKET REVENUE, BY PRODUCT TYPE 2012 - 2018 (USD MILLION) 
TABLE 6 U.S. COMPANION ANIMAL VACCINES MARKET REVENUE, BY PRODUCT TYPE 2012- 2018 (USD MILLION) 

Enquiry Before Buying


Free Market Analysis



In the last few years the U.S. vaccine market has grown incrementally. It still remains an attractive market characterized by rising prevalence of infectious diseases, government regulations for mandatory immunization, bucking up for next pandemic influenza, and rising global demand. The future of vaccine market is very luminous as major multinational firm such as GlaxoSmithKline, Sanofi, Merk, Novartis and Pfizer are investing significant amount in research & development and have huge product pipeline. Moreover, the U.S. is the largest market for vaccines globally hence most of the major players will target the U.S. market for strengthening their position. Vaccine demand in the U.S. is forecast to reach USD 17,429.6 million in 2018, growing at an estimated CAGR of 5.3% during 2012 - 2018.  

Human vaccine segment is attractive segment to invest in as it accounts for about 81.5% of the overall U.S. vaccine market due to rising prevalence of infectious diseases. The market is estimated to grow from USD 10,266.1 million in 2012 at a healthy CAGR during the analysis period. Pediatric and adult/adolescent vaccines market together will account for more than 77.78% of the overall Human vaccine market. 

Moreover, Animal Vaccine Market is expected to account for 18.5% of the overall U.S. vaccine market in 2018. The Animal Vaccine Market is forecast to grow at an estimated CAGR of 4.4% during the forecast period. 

The current U.S. vaccine market has large number of players both global and niche players. However, it is dominated by few global players. The U.S. vaccine market includes major players such as Sanofi-Aventis, Merck, GlaxoSmithKline, Pfizer, Novartis, Sanofi-Pasture, Bayer and Boehringer
 

To get discount on this report, just click on the button below.

To receive brochure, please click on the button below.

Share This Market Study!  

Upcoming Report

Payment
Copyright @ Transparency Market Research